Urinary symptoms must be frequent in Scleroderma. In one hand, mobility limitation by joint stiffness and skin sclerosis, forced diuresis due to heart involvement (cardiomyopathy or pulmonary hypertension), diuretics use and corticoid-induced hyperglycaemia, as well as narcotic medication use, puts patients at higher risk of secondary bladder filling and voiding dysfunction. In another hand, few case report and small sample observational studies have identified a specific sclerosis of the urinary tract. Those two mechanisms must be more frequent in the diffuse cutaneous form of scleroderma (dcSSc) compare to the limited one (lcSSc). But prevalence or incidence is unknown. Urinary symptoms are seldom reported by those suffering from them and are rarely part of a systemic evaluation. In a threatening disease, urinary symptoms assessment might seem to be of no priority. But LUTS have a real impact on many aspect of everyday living. Furthermore urinary tract involvement might predispose to urinary tract infection due to flow limitation and stagnation. Since it is an inner fibrosis it might be associated with a more aggressive form of disease conferring a greater loss of physical function, higher risk for hospital admission and death. Thus, identifying urinary symptoms would permit to address specific rehabilitation or medication therapy, in order to minimize the consequences of the bothersome symptoms and identify those subjects at higher risk of urinary infection, aggressive disease/loss of function or death. This study will also give basement to build an interventional study directed toward LUTS treatment in this population. In this prospective cohort we would like to: * Compare the prevalence of lower urinary tract symptoms (LUTS) in diffuse and limited forms of systemic sclerosis. * Determine the prevalence (at inclusion) and incidence (in a two years period) of LUTS among patients suffering from systemic sclerosis. * Evaluate the impact of LUTS symptoms on Quality of life. * Compare the discrimination ability of Cochin-hand score and HAQ score to predict incontinence in this population. * Evaluate the association between LUTS symptoms, hospital admission rate, urinary tract infection, mortality and loss of autonomy.
Study Type
OBSERVATIONAL
Enrollment
334
Hôpital Cochin
Paris, France
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera di Padova
Padova, Italy
Universtiy Hospital, Geneva
Geneva, Switzerland
Prevalence/incidence of urinary symptoms in scleroderma
Time frame: Inclusion and every year for 2 years
Short Form 36 Health Survey (SF-36)
Quality of life (lower, better)
Time frame: At inclusion and after 2 years
Mortality
Time frame: During two years
Urinary tract infection
Time frame: During two years
Incontinence Quality of Life (IQol)
Quality of life (0-100; higher, better), specific for urinary incontinence
Time frame: At inclusion and after 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.